Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
87.87
-2.24 (-2.49%)
Sep 2, 2025, 4:00 PM - Market closed
Revvity Revenue
Revvity had revenue of $720.28M in the quarter ending June 29, 2025, with 4.13% growth. This brings the company's revenue in the last twelve months to $2.80B, up 3.33% year-over-year. In the year 2024, Revvity had annual revenue of $2.76B with 0.16% growth.
Revenue (ttm)
$2.80B
Revenue Growth
+3.33%
P/S Ratio
3.78
Revenue / Employee
$254,406
Employees
11,000
Market Cap
10.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
| Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
| Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
| Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
| Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RVTY News
- 17 hours ago - Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina - Business Wire
- 15 days ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 27 days ago - Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics - Business Wire
- 5 weeks ago - Revvity Q2: Headwinds From China And Customers, Buy On Weakness - Seeking Alpha
- 5 weeks ago - Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook - Investopedia
- 5 weeks ago - Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More - Investopedia
- 5 weeks ago - Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga